The effect of iontophoresis and surfactant on transdermal apomorphine micro-emulsion treatment in patients with Parkinson's Disease

The effect of iontophoresis and surfactant on transdermal apomorphine micro-emulsion treatment in patients with Parkinson's Disease - Iontophoretic delivery of apomorphine micro-emulsion with iontophoresis

Status

Active, not recruiting

Phases

Phase 2

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON30219

Enrollment

Registered

2006-12-28

Start date

2006-11-14

Completion date

Unknown

Last updated

2024-05-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Parkinson parkinsonism Parkinson's disease

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: - Patients with parkinson's disease with at random fluctuations that are insufficiently medicated with oral parkinson medication -age > 18 -patient signed approved informed consent;-patient should be capable of understanding the protocol

Exclusion criteria

Exclusion criteria: - severe reaction on subcutaneous apomorphine test -little skin pigmentation combined with burned skin -instable internal pathology -changes in parkinson medication during the past month -Mini Mental State Examination

Design outcomes

Primary

Measure	Time frame
Clinical improvement - tapping score - standard scales for clinical improvement side-effects -scales -visual scoringsystem	—

Secondary

Measure	Time frame
apomorphine plasma concentration	—

Countries

Netherlands

Outcome results